Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039844 · ClinicalTrials.gov registry record · Phase 1
Study of Weekly LOC-paclitaxel Injection for Melanoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT01039844: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01039844 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01039844, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with metastatic melanoma. The safety of this drug and if it can control the disease is also being studied.
Interventions
- DRUG LOC-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-12 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039844
The ClinicalTrials.gov registry entry for NCT01039844 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LOC-paclitaxel is the first listed.
NCT01039844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039844 about?
NCT01039844 is a clinical study titled "Study of Weekly LOC-paclitaxel Injection for Melanoma". The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with metastatic melanoma. The safety of this drug and if it can control the disease is also being studied.
What is the current status of trial NCT01039844?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2009-12. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01039844?
The interventions under investigation include: LOC-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01039844?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.